Folate Nutritional Status among Psoriasis Patients not Exposed to Antifolate Drug

Author(s): Luciana Y. Tomita*, Andréia C. da Costa, Solange Andreoni, Luiza K.M. Oyafuso, Vânia D’Almeida, Fernando L.A. Fonseca, Ana C.L. Rocha, Clarice Kobata

Journal Name: Current Nutrition & Food Science

Volume 16 , Issue 4 , 2020


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: Folic acid fortification program has been established to prevent tube defects. However, concern has been raised among patients using anti-folate drug, i.e. psoriatic patients, a common, chronic, autoimmune inflammatory skin disease associated with obesity and smoking.

Objective: To investigate dietary and circulating folate, vitamin B12 (B12) and homocysteine (hcy) in psoriatic subjects exposed to the national mandatory folic acid fortification program.

Methods: Cross-sectional study using the Food Frequency Questionnaire, plasma folate, B12, hcy and psoriasis severity using the Psoriasis Area and Severity Index score. Median, interquartile ranges (IQRs) and linear regression models were conducted to investigate factors associated with plasma folate, B12 and hcy.

Results: 82 (73%) mild psoriasis, 18 (16%) moderate and 12 (11%) severe psoriasis. 58% female, 61% non-white, 31% former smokers, and 20% current smokers. Median (IQRs) were 51 (40, 60) years. Only 32% reached the Estimated Average Requirement of folate intake. Folate and B12 deficiencies were observed in 9% and 6% of the blood sample respectively, but hyperhomocysteinaemia in 21%. Severity of psoriasis was negatively correlated with folate and B12 concentrations. In a multiple linear regression model, folate intake contributed positively to 14% of serum folate, and negative predictors were psoriasis severity, smoking habits and saturated fatty acid explaining 29% of circulating folate.

Conclusion: Only one third reached dietary intake of folate, but deficiencies of folate and B12 were low. Psoriasis severity was negatively correlated with circulating folate and B12. Stopping smoking and a folate rich diet may be important targets for managing psoriasis.

Keywords: Diet, folate, fortification, homocysteine, psoriasis, vitamin B12.

[1]
Horton S. The economics of food fortification. J Nutr 2006; 136(4): 1068-71.
[http://dx.doi.org/10.1093/jn/136.4.1068] [PMID: 16549479]
[2]
Eichholzer M, Tönz O, Zimmermann R. Folic acid: a public-health challenge. Lancet 2006; 367(9519): 1352-61.
[http://dx.doi.org/10.1016/S0140-6736(06)68582-6] [PMID: 16631914]
[3]
De Wals P, Tairou F, Van Allen MI, et al. Reduction in neural-tube defects after folic acid fortification in Canada. N Engl J Med 2007; 357(2): 135-42.
[http://dx.doi.org/10.1056/NEJMoa067103] [PMID: 17625125]
[4]
Williams J, Mai CT, Mulinare J, et al. Centers for Disease Control and Prevention. Updated estimates of neural tube defects prevented by mandatory folic Acid fortification - United States, 1995-2011. MMWR Morb Mortal Wkly Rep 2015; 64(1): 1-5.
[PMID: 25590678]
[5]
Vollset SE, Clarke R, Lewington S, et al. B-Vitamin Treatment Trialists’ Collaboration. Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50,000 individuals. Lancet 2013; 381(9871): 1029-36.
[http://dx.doi.org/10.1016/S0140-6736(12)62001-7] [PMID: 23352552]
[6]
Qin T, Du M, Du H, Shu Y, Wang M, Zhu L. Folic acid supplements and colorectal cancer risk: meta-analysis of randomized controlled trials. Sci Rep 2015; 5: 12044.
[http://dx.doi.org/10.1038/srep12044] [PMID: 26131763]
[7]
Neuhouser ML, Cheng TY, Beresford SA, et al. Red blood cell folate and plasma folate are not associated with risk of incident colorectal cancer in the Women’s Health Initiative observational study. Int J Cancer 2015; 137(4): 930-9.
[http://dx.doi.org/10.1002/ijc.29453] [PMID: 25643945]
[8]
Chuang SC, Rota M, Gunter MJ, et al. Quantifying the dose-response relationship between circulating folate concentrations and colorectal cancer in cohort studies: a meta-analysis based on a flexible meta-regression model. Am J Epidemiol 2013; 178(7): 1028-37.
[http://dx.doi.org/10.1093/aje/kwt083] [PMID: 23863758]
[9]
Nisa N, Qazi MA. Prevalence of metabolic syndrome in patients with psoriasis. Indian J Dermatol Venereol Leprol 2010; 76(6): 662-5.
[http://dx.doi.org/10.4103/0378-6323.72462] [PMID: 21079309]
[10]
Icen M, Crowson CS, McEvoy MT, Dann FJ, Gabriel SE, Maradit Kremers H. Trends in incidence of adult-onset psoriasis over three decades: a population-based study. J Am Acad Dermatol 2009; 60(3): 394-401.
[http://dx.doi.org/10.1016/j.jaad.2008.10.062] [PMID: 19231638]
[11]
Raychaudhuri SP, Farber EM. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol 2001; 15(1): 16-7.
[http://dx.doi.org/10.1046/j.1468-3083.2001.00192.x] [PMID: 11451313]
[12]
Burch PR, Rowell NR. Mode of inheritance in psoriasis. Arch Dermatol 1981; 117(5): 251-2.
[http://dx.doi.org/10.1001/archderm.1981.01650050005005] [PMID: 7224653]
[13]
Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005; 64(Suppl. 2): ii18-23.
[http://dx.doi.org/10.1136/ard.2004.033217] [PMID: 15708928]
[14]
Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137(3): 280-4.
[PMID: 11255325]
[15]
Shikiar R, Heffernan M, Langley RG, Willian MK, Okun MM, Revicki DA. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial. J Dermatolog Treat 2007; 18(1): 25-31.
[http://dx.doi.org/10.1080/09546630601121060] [PMID: 17365264]
[16]
Choi J, Koo JY. Quality of life issues in psoriasis. J Am Acad Dermatol 2003; 49(2)(Suppl.): S57-61.
[http://dx.doi.org/10.1016/S0190-9622(03)01136-8] [PMID: 12894127]
[17]
Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007; 157(1): 68-73.
[http://dx.doi.org/10.1111/j.1365-2133.2007.07986.x] [PMID: 17553036]
[18]
Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286(3): 327-34.
[http://dx.doi.org/10.1001/jama.286.3.327] [PMID: 11466099]
[19]
Reed WB. Psoriatic arthritis. A complete clinical study of 86 patients. Acta Derm Venereol 1961; 41: 396-403.
[PMID: 14490976]
[20]
Gibson SH, Perry HO. Diabetes and psoriasis. AMA Arch Derm 1956; 74(5): 487-8.
[http://dx.doi.org/10.1001/archderm.1956.01550110031009] [PMID: 13361534]
[21]
Cohen AD, Dreiher J, Shapiro Y, et al. Psoriasis and diabetes: a population-based cross-sectional study. J Eur Acad Dermatol Venereol 2008; 22(5): 585-9.
[http://dx.doi.org/10.1111/j.1468-3083.2008.02636.x] [PMID: 18331320]
[22]
Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 2008; 159(4): 895-902.
[http://dx.doi.org/10.1111/j.1365-2133.2008.08707.x] [PMID: 18616778]
[23]
Nair RP, Ding J, Duffin KC, et al. Psoriasis bench to bedside: genetics meets immunology. Arch Dermatol 2009; 145(4): 462-4.
[http://dx.doi.org/10.1001/archdermatol.2009.73] [PMID: 19380669]
[24]
Hercogová J, Ricceri F, Tripo L, Lotti T, Prignano F. Psoriasis and body mass index. Dermatol Ther 2010; 23(2): 152-4.
[http://dx.doi.org/10.1111/j.1529-8019.2010.01309.x] [PMID: 20415822]
[25]
Setty AR, Curhan G, Choi HK. Smoking and the risk of psoriasis in women: Nurses’ Health Study II. Am J Med 2007; 120(11): 953-9.
[http://dx.doi.org/10.1016/j.amjmed.2007.06.020] [PMID: 17976422]
[26]
Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses’ Health Study II. Arch Intern Med 2007; 167(15): 1670-5.
[http://dx.doi.org/10.1001/archinte.167.15.1670] [PMID: 17698691]
[27]
Gao Z, Tseng CH, Strober BE, Pei Z, Blaser MJ. Substantial alterations of the cutaneous bacterial biota in psoriatic lesions. PLoS One 2008; 3(7)e2719
[http://dx.doi.org/10.1371/journal.pone.0002719] [PMID: 18648509]
[28]
Shane B. Folate and vitamin B12 metabolism: overview and interaction with riboflavin, vitamin B6, and polymorphisms. Food Nutr Bull 2008; 29(2)(Suppl.): S5-S16.
[http://dx.doi.org/10.1177/15648265080292S103] [PMID: 18709878]
[29]
Karabudak O, Ulusoy RE, Erikci AA, Solmazgul E, Dogan B, Harmanyeri Y. Inflammation and hypercoagulable state in adult psoriatic men. Acta Derm Venereol 2008; 88(4): 337-40.
[PMID: 18709301]
[30]
Malerba M, Gisondi P, Radaeli A, Sala R, Calzavara Pinton PG, Girolomoni G. Plasma homocysteine and folate levels in patients with chronic plaque psoriasis. Br J Dermatol 2006; 155(6): 1165-9.
[http://dx.doi.org/10.1111/j.1365-2133.2006.07503.x] [PMID: 17107384]
[31]
Vanizor Kural B, Orem A, Cimşit G, Yandi YE, Calapoglu M. Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant-antioxidant system in patients with psoriasis. Clin Chim Acta 2003; 328(1-2): 71-82.
[http://dx.doi.org/10.1016/S0009-8981(02)00373-X] [PMID: 12559600]
[32]
Salim A, Tan E, Ilchyshyn A, Berth-Jones J. Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial. Br J Dermatol 2006; 154(6): 1169-74. Internet
[http://dx.doi.org/10.1111/j.1365-2133.2006.07289.x] [PMID: 16704650]
[33]
Chládek J, Simková M, Vanecková J, et al. The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis. Eur J Clin Pharmacol 2008; 64(4): 347-55.
[http://dx.doi.org/10.1007/s00228-007-0442-x] [PMID: 18163165]
[34]
Strober BE, Menon K. Folate supplementation during methotrexate therapy for patients with psoriasis. J Am Acad Dermatol 2005; 53(4): 652-9.
[http://dx.doi.org/10.1016/j.jaad.2005.06.036] [PMID: 16198787]
[35]
Schmitt J, Wozel G. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology (Basel) 2005; 210(3): 194-9.
[http://dx.doi.org/10.1159/000083509] [PMID: 15785046]
[36]
Martins GA, Arruda L, Mugnaini ASB. Validação de questionários de avaliação da qualidade de vida em pacientes de psoríase. An Bras Dermatol 2004; 79(5): 521-35.
[http://dx.doi.org/10.1590/S0365-05962004000500002]
[37]
Finlay AY, Khan GK, Luscombe DK, Salek MS. Validation of sickness impact profile and psoriasis disability index in psoriasis. Br J Dermatol 1990; 123(6): 751-6.
[http://dx.doi.org/10.1111/j.1365-2133.1990.tb04192.x] [PMID: 2265090]
[38]
Joint WHO/FAO Expert Consultation on Diet and the Prevention of Chronic DiseaseDiet, nutrition and the prevention of chronic diseases. In: WHO Technical Report Series, 916. Geneva. 2002.
[39]
WHO. WHO STEPwise approach for surveillance (STEPS). Geneva: World Health Organization 2008.
[40]
Cardoso MA, Kida AA, Tomita LY, Stocco PR. Reproducibility and validity of a food frequency questionnaire among women of Japanese ancestry living in Brazil. Nutr Res 2001; 21(5): 725-33.
[http://dx.doi.org/10.1016/S0271-5317(01)00283-4]
[41]
Tomita LY, Almeida LC, Roteli-Martins C, D’Almeida V, Cardoso MA, Team BS. BRINCA Study Team. Dietary predictors of serum total carotene in low-income women living in São Paulo, south-east Brazil. Public Health Nutr 2009; 12(11): 2133-42.
[http://dx.doi.org/10.1017/S1368980009005321] [PMID: 19335942]
[42]
Block G, Coyle LM, Hartman AM, Scoppa SM. Revision of dietary analysis software for the Health Habits and History Questionnaire. Am J Epidemiol 1994; 139(12): 1190-6.
[http://dx.doi.org/10.1093/oxfordjournals.aje.a116965] [PMID: 8209877]
[43]
U.S. Department of Agriculture. USDA National Nutrient Database for Standard Reference,Release 27 Nutrient Data Laboratory Home Page . 2014.Available from: http: //www.ars.usda.gov/ba/bhnrc/ndl
[44]
Anvisa. Cartilha sobre Boas Práticas para Serviços de Alimentação Resolução-RDC no 216/2004 Agência Nac Vigilância Sanitária 2004; 1-43.
[45]
Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and its Panel on Folate, Other B Vitamins and C. Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline 1998; 196-305.Available from: http: //www.ncbi.nlm.nih.gov/pubmed/23193625
[46]
Lee JE, Wei EK, Fuchs CS, et al. Plasma folate, methylenetetrahydrofolate reductase (MTHFR), and colorectal cancer risk in three large nested case-control studies. Cancer Causes Control 2012; 23(4): 537-45.
[http://dx.doi.org/10.1007/s10552-012-9911-3] [PMID: 22367721]
[47]
Gascón TM, Schindler F, Oliveira CG, et al. Evaluation of chemiluminescence method for the analysis of plasma homocysteine and comparison with HPLC method in children samples. Einstein (Sao Paulo) 2010; 8(2): 187-91.
[http://dx.doi.org/10.1590/s1679-45082010ao1499] [PMID: 26760001]
[48]
Yamashita EK, Teixeira BM, Yoshihara RN, et al. Systemic chemotherapy interferes in homocysteine metabolism in breast cancer patients. J Clin Lab Anal 2014; 28(2): 157-62. [A].
[http://dx.doi.org/10.1002/jcla.21660] [PMID: 24395112]
[49]
de Benoist B. Conclusions of a WHO Technical Consultation on folate and vitamin B12 deficiencies. Food Nutr Bull 2008; 29(2)(Suppl.): S238-44.
[http://dx.doi.org/10.1177/15648265080292S129] [PMID: 18709899]
[50]
Carmel R, Green R, Rosenblatt DS, Watkins D. Update on cobalamin, folate, and homocysteine. Hematol Am Soc Hematol Educ Progr 2003; pp. 62-81.
[51]
Victora CG, Huttly SR, Fuchs SC, Olinto MT. The role of conceptual frameworks in epidemiological analysis: a hierarchical approach. Int J Epidemiol 1997; 26(1): 224-7.
[http://dx.doi.org/10.1093/ije/26.1.224] [PMID: 9126524]
[52]
Kleinbaum DG, Kupper LL, Nezam A, Muller KE. Applied regression analysis and other multivariable methods. 3rd ed. Duxbury Press: USA 1997.
[53]
Trumbo P, Yates AA, Schlicker S, Poos M. Dietary reference intakes: vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc. J Am Diet Assoc 2001; 101(3): 294-301.
[http://dx.doi.org/10.1016/S0002-8223(01)00078-5] [PMID: 11269606]
[54]
Institute of Medicine. Dietary Reference Intakes. The National Academies Press : Washington, D.C. 2005.
[55]
Llanos A, Hertrampf E, Cortes F, Pardo A, Grosse SD, Uauy R. Cost-effectiveness of a folic acid fortification program in Chile. Health Policy 2007; 83(2-3): 295-303.
[http://dx.doi.org/10.1016/j.healthpol.2007.01.011] [PMID: 17363103]
[56]
Marchioni DML, Verly E Jr, Steluti J, Cesar CLG, Fisberg RM. [Folic acid intake before and after mandatory fortification: a population-based study in São Paulo, Brazil]. Cad Saude Publica 2013; 29(10): 2083-92.
[http://dx.doi.org/10.1590/0102-311X00084712] [PMID: 24127102]
[57]
IBGE. Instituto Brasileiro de Geografia e Estatística, Coordenação de Trabalho e RendimentoPesquisa de Orçamentos Familiares: 2008-2009 Análise do Consumo Alimentar Pessoal no Brasil [Internet] Biblioteca do Ministerio do Planejamento, Orçamento e Gestão. 2011; 150 .Available from: http: //biblioteca.ibge.gov.br/ visualizacao/livros/liv50063.pdf
[58]
Rodrigues HG, Gubert MB, Santos LMP. Folic acid intake by pregnant women from Vale do Jequitinhonha, Brazil, and the contribution of fortified foods. Arch Latinoam Nutr 2015; 65(1): 27-35.
[PMID: 26320303]
[59]
Choumenkovitch SF, Selhub J, Wilson PWF, Rader JI, Rosenberg IH, Jacques PF. Folic acid intake from fortification in United States exceeds predictions. J Nutr 2002; 132(9): 2792-8.
[http://dx.doi.org/10.1093/jn/132.9.2792] [PMID: 12221247]
[60]
Fulgoni VL III, Keast DR, Bailey RL, Dwyer J. Foods, fortificants, and supplements: Where do Americans get their nutrients? J Nutr 2011; 141(10): 1847-54.
[http://dx.doi.org/10.3945/jn.111.142257] [PMID: 21865568]
[61]
Soeiro BT, Boen TR, Wagner R, Lima-Pallone JA. Physico-chemical quality and homogeneity of folic acid and iron in enriched flour using principal component analysis. Int J Food Sci Nutr 2009; 60(S7)(Suppl. 7): 167-79.
[http://dx.doi.org/10.1080/09637480902769567] [PMID: 19399673]
[62]
Chakraborty H, Nyarko KA, Goco N, et al. Folic Acid Fortification and Women’s Folate Levels in Selected Communities in Brazil - A First Look. Int J Vitam Nutr Res Int Zeitschrift für Vitamin- und Ernährungsforschung J Int Vitaminol Nutr 2014; 84(5-6): 286-94.
[63]
Britto JC, Cançado R, Guerra-Shinohara EM. Concentrations of blood folate in Brazilian studies prior to and after fortification of wheat and cornmeal (maize flour) with folic acid: a review. Rev Bras Hematol Hemoter 2014; 36(4): 275-86.
[http://dx.doi.org/10.1016/j.bjhh.2014.03.018] [PMID: 25031167]
[64]
Kural VB, Örem A, Cimşit G, Uydu HA, Yandi YE, Alver A. Plasma homocysteine and its relationships with atherothrombotic markers in psoriatic patients. Clin Chim Acta 2003; 332(1-2): 23-30.
[http://dx.doi.org/10.1016/S0009-8981(03)00082-2] [PMID: 12763276]
[65]
Giannoni M, Consales V, Campanati A, et al. Homocysteine plasma levels in psoriasis patients: our experience and review of the literature. J Eur Acad Dermatol Venereol 2015; 29(9): 1781-5.
[http://dx.doi.org/10.1111/jdv.13023] [PMID: 25809089]
[66]
Nygård O, Vollset SE, Refsum H, Brattström L, Ueland PM. Total homocysteine and cardiovascular disease. J Intern Med 1999; 246(5): 425-54.
[http://dx.doi.org/10.1046/j.1365-2796.1999.00512.x] [PMID: 10583714]
[67]
Cakmak SK, Gül U, Kiliç C, Gönül M, Soylu S, Kiliç A. Homocysteine, vitamin B12 and folic acid levels in psoriasis patients. J Eur Acad Dermatol Venereol 2009; 23(3): 300-3.
[http://dx.doi.org/10.1111/j.1468-3083.2008.03024.x] [PMID: 19207655]
[68]
Smith AD, Kim YI, Refsum H. Is folic acid good for everyone? Am J Clin Nutr 2008; 87(3): 517-33.
[http://dx.doi.org/10.1093/ajcn/87.3.517] [PMID: 18326588]
[69]
Stein CJ, Colditz GA. Modifiable risk factors for cancer. Br J Cancer 2004; 90(2): 299-303.
[http://dx.doi.org/10.1038/sj.bjc.6601509] [PMID: 14735167]
[70]
Love TJ, Qureshi AA, Karlson EW, Gelfand JM, Choi HK. Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003-2006. Arch Dermatol 2011; 147(4): 419-24.
[http://dx.doi.org/10.1001/archdermatol.2010.370] [PMID: 21173301]
[71]
Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006; 298(7): 321-8.
[http://dx.doi.org/10.1007/s00403-006-0703-z] [PMID: 17021763]
[72]
Hamminga EA, van der Lely AJ, Neumann HA, Thio HB. Chronic inflammation in psoriasis and obesity: implications for therapy. Med Hypotheses 2006; 67(4): 768-73.
[http://dx.doi.org/10.1016/j.mehy.2005.11.050] [PMID: 16781085]
[73]
Schön MP, Boehncke WH. Psoriasis. N Engl J Med 2005; 352(18): 1899-912.
[http://dx.doi.org/10.1056/NEJMra041320] [PMID: 15872205]
[74]
Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296(14): 1735-41.
[http://dx.doi.org/10.1001/jama.296.14.1735] [PMID: 17032986]
[75]
Naldi L, Chatenoud L, Linder D, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005; 125(1): 61-7.
[http://dx.doi.org/10.1111/j.0022-202X.2005.23681.x] [PMID: 15982303]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 4
Year: 2020
Published on: 13 July, 2020
Page: [543 - 553]
Pages: 11
DOI: 10.2174/1573401314666180702100301
Price: $65

Article Metrics

PDF: 12
HTML: 2